Abaloparatide (brand name Tymlos) is a human parathyroid hormone related peptide [PTHrP(1-34)]
analog indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R).
This results in activation of the cAMP signaling pathway in target cells. In rats and monkeys,
abaloparatide had an anabolic effect on bone, demonstrated by increases in BMD and bone
mineral content (BMC) that correlated with increases in bone strength at vertebral and/or
nonvertebral sites. Abaloparatide was approved in April 28, 2017 by the FDA (as Tymlos) for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1793 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24078470 |
0.087 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TYMLOS Approved UseTYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk
for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or
patients who have failed or are intolerant to other available osteoporosis therapy. In
postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and
nonvertebral fractures. Launch Date1.49325126E12 |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis. | 2018 Feb |
|
Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide. | 2018 Jun |
|
Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide. | 2018 Jun |
|
Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. | 2018 Mar |
Patents
Sample Use Guides
Recommended dose is 80 ug subcutaneously once daily; patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.
Administer as a subcutaneous injection into periumbilical region of abdomen. Administer initially where the patient can sit or lie down in case symptoms of orthostatic hypotension occur.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26562265
cAMP signaling potency of Abaloparatide in PTHR1-expressing cells was found to be approximately 5-fold greater than that of PTH (1–34) (EC50 = ∼0.087 vs ∼0.44nM; P = .0009).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000193453
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB180168
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
247062-33-5
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
9794
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
CHEMBL3301581
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
5232
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
C158818
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
506422-98-6
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
ALTERNATIVE | |||
|
AVK0I6HY2U
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
76943386
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
1921069
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
m12003
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
AVK0I6HY2U
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
DB05084
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
Abaloparatide
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
AB-124
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY | |||
|
DTXSID201027906
Created by
admin on Sat Dec 16 09:43:30 UTC 2023 , Edited by admin on Sat Dec 16 09:43:30 UTC 2023
|
PRIMARY |
ACTIVE MOIETY